Phase 1 Dose Escalation and Cohort Expansion Study of Anti-PD-1 Monoclonal Antibody TSR-042 in Advanced Solid Tumors

The primary objective of this study is to evaluate the safety and tolerability of **TSR-042**, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors. This is clinically relevant as it aims to determine the potential of TSR-042 to be a viable treatment option for individuals with these types of malignancies, which are often challenging to treat with existing therapies. The study focuses on understanding the adverse effects and establishing a safe dosage range for future clinical applications.

The clinical trial involves a total of **425 participants** diagnosed with **advanced solid tumors**. The study population includes both male and female subjects, with an age range spanning from 18 to 65 years. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The selection process aimed to encompass a diverse group within the specified age range and health condition, ensuring a comprehensive evaluation of the treatment's effects across a representative sample of the affected population.

The clinical trial is a **Phase 1** study designed to evaluate the safety, tolerability, and preliminary efficacy of TSR-042, an anti-PD-1 monoclonal antibody, in patients with **advanced solid tumors**. The trial employs a **randomized**, **double-blind**, and **controlled** design to ensure the reliability and validity of the results. The estimated duration of the trial spans from March 7, 2016, to October 28, 2027, allowing for comprehensive data collection and analysis over an extended period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a thorough medical evaluation, including a review of the patient's medical history and current health status. Following successful screening, participants will be enrolled in the trial and randomly assigned to receive either the investigational drug or a control. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' response to the treatment, assess any adverse events, and ensure adherence to the study protocol. These visits will include physical examinations, laboratory tests, and imaging studies as necessary.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, a final assessment will be conducted to evaluate the overall outcomes and any long-term effects of the treatment. The expected length of participant involvement will vary depending on individual response and the progression of the disease, but it is anticipated to last several months. Conditions that may lead to early termination from the study include significant adverse reactions, disease progression, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. Consequently, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. As such, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial investigation into the safety and potential efficacy of the intervention. The trial is scheduled to conclude by October 28, 2027, with recruitment having commenced on March 7, 2016. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase 1 trials typically focus on safety and dosage, with preliminary efficacy being a secondary consideration. The assessment of efficacy will likely involve the collection and analysis of data at predetermined intervals throughout the trial duration. The methods and tools for measuring efficacy are not specified, but standard practices in clinical trials include the use of validated scales, laboratory tests, and patient-reported outcomes. The trial's design and execution will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the findings.